TAK News and Press, Takeda Pharmaceutical Company Limited American Depositary Shares From 06/21/24

− Approval Based on Results from Positive, Global, Phase 3 FRESCO-2 Trial − FRUZAQLA (fruquintinib) is the First Novel Targeted Therapy in the EU for Metastatic Colorectal Cancer (mCRC) Regardless of Biomarker Status in Over a Decade Takeda ( TSE:4502/N...

Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older Canada NewsWire HyQvia®, which may be administered at home, will provide children and adolesc...

2024-06-18 12:27:47 ET More on Ovid Therapeutics Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024 Ovid stock plunges 66% on failed studies for soticlestat Ovid Therapeutics gains on bullish view at Wedbush Seeking Alpha’s Quant...

Favorable Findings from the Longest Public Clinical Study in CIDP Support HYQVIA as an Effective Long-Term Treatment Option for Maintaining Stable Disease Course in CIDP ADVANCE Clinical Program Reflects Takeda’s Commitment to Continued Research on the Role of Immunoglobuli...

2024-06-17 10:40:00 ET Summary Shionogi optioned rights for two candidates targeting cochlear synaptopathy, including one that is poised to start a Phase II trial. XtalPi raised US$126.8 million in a Hong Kong IPO, the third-largest Hong Kong IPO of the year. Takeda entered a ...

2024-06-17 09:59:01 ET More on Ovid Therapeutics, Takeda Pharmaceutical, etc. Takeda: Strong Growth Catalysts And Maturing Pipeline Continue To Limit Downside Risk Takeda Pharmaceutical Company Limited (TAK) Fiscal Year 2023 Earnings Call Transcript Takeda Pharmaceut...

SKYLINE Study in Dravet Syndrome Narrowly Missed its Primary Endpoint of Reduction in Convulsive Seizure Frequency and Showed Clinically Meaningful and Nominally Significant Effects in Multiple Key Secondary Efficacy Endpoints SKYWAY Study in Lennox-Gastaut Syndrome Missed its Primary End...

2024-06-14 08:27:50 ET More on Takeda Pharmaceutical Takeda: Strong Growth Catalysts And Maturing Pipeline Continue To Limit Downside Risk Takeda Pharmaceutical Company Limited (TAK) Fiscal Year 2023 Earnings Call Transcript Takeda Pharmaceutical Company Limited 2023...

− Takeda to Receive Exclusive Option to License Global Rights to Olverembatinib in All Territories Outside of Mainland China, Hong Kong, Macau, Taiwan and Russia − Olverembatinib Has the Potential to Address Significant Unmet Need for Patients with Chronic Myeloid Le...

The New Expanded Partnership Will Aim to Support the Dismantling of Systemic Barriers to Equity and Help Strengthen the Health Workforce in Massachusetts The Existing Global Partnership Has Provided Screening and Diagnostic Services to Over 8 Million People in Community Settings ...